APRA Stress Test: Home Insurance Gap Impact on Financial Resilience

APRA's Insurance Climate Vulnerability Assessment (Insurance CVA) stress test indicates that a widening home insurance protection gap in Australia could significantly impact financial system resilience. The assessment projects that the proportion of uninsured homes could rise from one in seven to one in four by 2050 under severe climate scenarios.

CVS Pharmacy v. Swyft Inc. - Breach of Settlement Agreement

CVS Pharmacy has filed a lawsuit against Swyft Inc. alleging breach of a settlement agreement and a master rental and services agreement. The complaint also includes claims for false designation of origin under the Lanham Act and unfair competition under California state law. The case was filed in the U.S. District Court for the Northern District of California.

BaFin Warns Consumers About Wertede.com and Wertede.cc Services

BaFin has issued a warning to consumers regarding the websites wertede(.)com and wertede(.)cc. The operator is suspected of providing financial and investment services without the necessary authorization from BaFin, which is a violation of German law.

BaFin Warns Festgeldplan.com About Website and Identity Fraud

BaFin, the German financial supervisory authority, has issued a warning regarding the website festgeldplan.com for offering financial services without authorization and engaging in identity fraud. The operators falsely claim affiliation with the BaFin-supervised WPV Advisory & Asset Management GmbH & Co. KG. Consumers are advised to exercise extreme caution with online investment offers.

BaFin Warns Consumers About panda-financial.com

BaFin has issued a warning to consumers regarding the website panda-financial.com, stating that its operators are offering banking, financial, and cryptoasset services without the required authorization. The warning emphasizes that these services require BaFin authorization to be offered legally in Germany.

Marriage of Nevin - Montana Supreme Court

The Montana Supreme Court has issued a decision in the Marriage of Nevin case, docket number DA 25-0307. The court affirmed in part and reversed in part the lower court's decision. This is a non-precedential ruling.

Montana Supreme Court Reverses YC Properties v. Roaring Lion Ranch

The Montana Supreme Court reversed and remanded the case of Roaring Lion Ranch, LLC et al. v. YC Properties. The court found that the District Court erred in converting YC Properties' motion to dismiss into a motion for summary judgment, which led to the dismissal of the plaintiffs' claims with prejudice. The case originated from a dispute over water rights.

State v. Pratt - Affirmation of Dismissal of Sexual Offender Registration Charge

The Montana Supreme Court affirmed the dismissal of charges against Daniel Santos Pratt for failure to register as a sexual offender. The court ruled that the 2023 Sexual or Violent Offender Registration Act (SVORA) could not be retroactively applied to Pratt, whose conviction predated the 2007 amendments to the act, due to Ex Post Facto Clause violations.

State v. Sanchez - Montana Supreme Court Ruling

The Montana Supreme Court reversed in part and remanded a ruling in State v. Sanchez. The court found that the District Court's disposition illegally extended the defendant's sentence by including the probationary period in the revocation of the suspended portion. The case is remanded for correction of the disposition.

State v. Trombley - Bail Jumping Statute Unconstitutionally Vague

The Montana Supreme Court affirmed a lower court's decision in State v. Trombley, ruling that the state's bail jumping statute (§ 45-7-308, MCA) is not unconstitutionally vague. The court found that the statute sufficiently defined the offense and that the State had alleged sufficient facts to establish probable cause.

Pinnacle Property Management Services, LLC v. Tina L. West - Case Dismissed

The Texas Court of Appeals, 3rd District, has dismissed the appeal in Pinnacle Property Management Services, LLC d/b/a Cushman & Wakefield U.S., Inc. v. Tina L. West. The dismissal is for want of prosecution due to the appellant's failure to file a required brief by the established deadline.

Yaseen Naz v. State of Texas - Murder Appeal Dismissed

The Texas Court of Appeals, 3rd District, has dismissed the criminal appeal in Yaseen Naz v. The State of Texas. The dismissal was granted upon the appellant's motion, as signed by both the appellant and his attorney, in accordance with Texas Rule of Appellate Procedure 42.2(a). This action resolves the appellate proceedings for this specific case.

Tennessee Court of Appeals Opinion on Parental Rights Termination

The Tennessee Court of Appeals vacated and remanded a juvenile court's judgment regarding the termination of parental rights. The court found that the juvenile court misapplied the law concerning persistent conditions and failed to provide sufficient factual findings for both the mother and father. The case is remanded for proper legal analysis and factual findings.

Walker & Associates, Inc. v. Cecilia Walker Heffington - Settlement Agreement Enforcement

The Tennessee Court of Appeals affirmed a trial court's ruling enforcing a settlement agreement between Walker & Associates, Inc. and Cecilia Walker Heffington. The court found that the parties had reached an enforceable agreement following an evidentiary hearing.

USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators

The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.

USPTO Patent Grant US12582652B2 for Ion Channel Modulator

The USPTO has granted patent US12582652B2 to Praxis Precision Medicines, Inc. for a novel ion channel modulator compound. The patent covers methods of treating neurological disorders and conditions associated with neuronal excitability.

Biomaterial with functionalized tyrosine, preparation method, pharmaceutical composition

The USPTO has granted a patent (US12583818B2) for a method to prepare a biomaterial with selectively functionalized tyrosine and a pharmaceutical composition containing it. This innovation aims to improve the efficacy of biomaterial drugs by ensuring selective coupling to tyrosine without affecting other amino acids or the biomaterial's inherent activity.

USPTO Patent US12583820B2: Antivirals against coronavirus

The USPTO has granted patent US12583820B2 to Kansas State University Research Foundation for broad spectrum antivirals against coronaviruses. The patent covers specific chemical compounds designed to inhibit viral replication.

Omecamtiv Mecarbil Salt and Preparation Process

The USPTO has granted US Patent 12583821B2 to Cytokinetics, Inc. for a specific salt form of omecamtiv mecarbil and its preparation process. This patent covers the dihydrochloride salt form, related compositions, and methods of use, primarily impacting pharmaceutical development and intellectual property.

USPTO Patent Grant: Benzylamine Derivative for Anti-Tumor Efficacy

The USPTO has granted a patent (US12583822B2) to the Academy of Military Medical Sciences for a benzylamine derivative with potential anti-tumor efficacy. The patent covers the derivative, its preparation method, and its use in treating PD-1/PD-L1-related diseases.

Redona Therapeutics Cancer Treatment Compounds Patent Grant

The USPTO has granted Redona Therapeutics, Inc. a patent (US12583825B2) for novel cancer treatment compounds. The patent covers specific benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives and their use in treating neoplastic diseases.

USPTO Patent for Acetic Acid Derivatives as Safeners

The USPTO has granted a patent (US12583826B2) to Bayer Aktiengesellschaft for acetic acid derivatives and salts thereof, intended for use as safeners in crop protection compositions. These compounds aim to reduce the phytotoxic effects of agrochemicals, particularly herbicides.

USPTO Patent Grant: Process for Ethyleneamines and Ethanolamines Manufacture

The USPTO has granted patent US12583827B2 to BASF SE for a new process to manufacture ethyleneamines and ethanolamines. The patent details a two-step process involving the conversion of glycolaldehyde derivatives and an aminating agent, followed by hydrogenation.

USPTO Patent US12583828B2: Aromatic Carbonyl Compounds Preparation Process

The USPTO has granted patent US12583828B2 to BASF SE for a process to prepare aromatic carbonyl compounds. The patent describes a catalytic oxidation method using molecular oxygen, a cobalt(II) salt, and N,N′,N″-trihydroxyisocyanuric acid (THICA).

USPTO Patent Grant: Oxetane Derivative Synthesis Method by Microreactor

The USPTO has granted a patent (US12583830B2) for a microreactor-based synthesis method for oxetane derivatives. The patent, assigned to Changzhou Tronly Advanced Electronic Materials Co., Ltd., details a process that improves efficiency, yield, and safety compared to traditional methods.

USPTO Patent Grant US12583831B2 for Hydrogenation Processes

The USPTO has granted patent US12583831B2 to Archer-Daniels-Midland Company for selective hydrogenation processes and catalysts. The patent covers methods for upgrading impure feedstocks, such as those derived from biomass, to increase the concentration of valuable intermediates like glycolaldehyde and hydroxyacetone.

USPTO Patent Grant: Diastereomer-Enriched Odorant Mixture Preparation

The USPTO has granted patent US12583833B2 to Symrise AG for a distillative process to prepare a diastereomer-enriched odorant mixture. The patent covers the process, the enriched mixture, and its use in perfumery to impart or enhance floral odor notes.

USPTO Patent Grant: Bacterial Infection Treatment Compound

The USPTO has granted a patent (US12583834B2) for a compound and pharmaceutical composition designed to treat bacterial infections by inhibiting Mfd activity. The patent was filed on February 19, 2021, and is assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT.

USPTO Patent Grant: PD-L1 Antagonist Compound

The USPTO has granted a patent (US12583839B2) to ADLAI NORTYE BIOPHARMA CO., LTD. for a PD-L1 antagonist compound and its pharmaceutical composition. The patent covers compounds of Formula (I) and their use in treating immune-related disorders.

USPTO Patent US12583840B2 for Androgen Receptor Antagonists Preparation

The USPTO has granted patent US12583840B2 to Orion Corporation for a method of preparing androgen receptor antagonists and their intermediates. The patent details a process using a heterogeneous palladium catalyst for the preparation of a specific benzonitrile compound useful in the synthesis of carboxamide-structured androgen receptor antagonists.

USPTO Patent Grant for Insomnia and Depression Compound

The USPTO has granted a patent (US12583841B2) to Breakthrough Pharmaceuticals Inc. for a tetrahydropyrrolocyclic compound and its application in preparing drugs to treat insomnia and depression by targeting the selective orexin-2 receptor. The patent was filed on January 27, 2022, and granted on March 24, 2026.

USPTO Patent Grant: Crystal Form of Nitroxoline Prodrug

The USPTO has granted patent US12583835B2 for a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing it, and its preparation and application. The patent, assigned to Jiangsu Yahong Meditech Co., Ltd., describes crystal forms A and B with improved properties for industrial production and drug efficacy compared to nitroxoline.

USPTO Patent US12583838B2 for Kinase Inhibitors

The USPTO has granted patent US12583838B2 to Insilico Medicine Hong Kong Limited for kinase inhibitors designed for disease treatment. The patent covers specific compounds and their use in pharmaceutical compositions and methods for treating diseases.

USPTO Patent Grant US12583844B2: Hydantoin MMP Inhibitors

The USPTO has granted patent US12583844B2 to Foresee Pharmaceuticals USA, Inc. for hydantoin-based compounds that act as inhibitors of matrix metalloproteinases (MMPs), particularly MMP-12. The patent covers compositions and methods for treating various diseases mediated by MMP-12.

USPTO Patent Grant for Trinucleotide Repeat Disease Treatment

The USPTO has granted a patent (US12583845B2) to The Research Foundation for The State University of New York for compositions and methods to treat diseases involving trinucleotide repeats. The patent covers novel compounds and synthesis processes aimed at inhibiting microsatellite promoted expression of deleterious expansions.

USPTO Patent Grant: Benzopyran Derivatives as CRAC Inhibitors

The USPTO has granted a patent (US12583846B2) for benzopyran derivatives identified as CRAC inhibitors. The patent, filed on September 25, 2020, covers compounds represented by a specific formula, isomers, or pharmaceutically acceptable salts thereof, and their application in preparing CRAC inhibitors.

USPTO Patent Grant for Fluorinated Pyrimidine Compound Production

The USPTO has granted a patent (US12583847B2) to UNIMATEC CO., LTD. for a fluorinated pyrimidine compound and its production method. The patent covers specific chemical structures and synthesis processes, with a filing date of March 16, 2022.

USPTO Patent US12583848B2: Isoxazole Derivatives for Viral Infections

The USPTO has granted patent US12583848B2 to Universitätsklinikum Jena for isoxazole-3-carboxamide derivatives used in treating viral infections. The patent describes compounds effective against various viruses, including resistant strains, with low induction of cytochrome P4503A4.

USPTO Patent US12583849B2 for KCNT1 Inhibitors

The USPTO has granted patent US12583849B2 to PRAXIS PRECISION MEDICINES, INC. for KCNT1 inhibitors and methods of use. This patent covers compounds and compositions for treating neurological diseases, conditions related to excessive neuronal excitability, and gain-of-function mutations in genes like KCNT1.

USPTO Patent Grant: Pyrazine Derivatives for Pest Control

The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.

USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy

The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.

USPTO Patent Grant for BCL-2 Inhibitors

The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.

Amgen KRAS G12C Inhibitors Patent Granted

The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.

USPTO Patent US12583857B2 for Anti-liferative Agents

The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.

Genentech, Inc. Granted Patent for TDO2 Inhibitors

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

USPTO Patent Grant for API Crystalline Form Preparation

The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.

USPTO Grants Patent for Nanoporous Material for Ion Channels

The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.

Organic EL Device with Different Host Materials

The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.

Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted

The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.